Research And Development Expense of Fresenius Medical Care AG from 31 Dec 2015 to 31 Dec 2024

Taxonomy & unit
ifrs-full: EUR
Summary
Fresenius Medical Care AG quarterly and annual Research And Development Expense in EUR history and change rate from 31 Dec 2015 to 31 Dec 2024.
  • Fresenius Medical Care AG Research And Development Expense for the quarter ending 31 Dec 2024 was €50,060,000, a 24% decline year-over-year.
  • Fresenius Medical Care AG Research And Development Expense for the twelve months ending 31 Dec 2024 was €183,493,000, a 21% decline year-over-year.
  • Fresenius Medical Care AG annual Research And Development Expense for 2024 was €183,493,000, a 21% decline from 2023.
  • Fresenius Medical Care AG annual Research And Development Expense for 2023 was €231,970,000, a 1.5% increase from 2022.
  • Fresenius Medical Care AG annual Research And Development Expense for 2022 was €228,624,000, a 3.6% increase from 2021.
Source SEC data
View on sec.gov
Research And Development Expense, Trailing 12 Months (EUR)
Research And Development Expense, Quarterly (EUR)
Research And Development Expense, YoY Quarterly Change (%)
Research And Development Expense, Annual (EUR)
Research And Development Expense, YoY Annual Change (%)

Fresenius Medical Care AG Quarterly Research And Development Expense (EUR)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 €183,493,000 €50,060,000 -€15,925,000 -24% 01 Oct 2024 31 Dec 2024 20-F 25 Feb 2025 2024 FY
Q3 2024 €199,418,000 €40,047,000 -€12,994,000 -24% 01 Jul 2024 30 Sep 2024 6-K 05 Nov 2024 2024 Q3
Q2 2024 €212,412,000 €45,585,000 -€11,599,000 -20% 01 Apr 2024 30 Jun 2024 6-K 30 Jul 2024 2024 Q2
Q1 2024 €224,011,000 €47,801,000 -€7,959,000 -14% 01 Jan 2024 31 Mar 2024 6-K 07 May 2024 2024 Q1
Q4 2023 €231,970,000 €65,985,000 +€3,936,000 +6.3% 01 Oct 2023 31 Dec 2023 20-F 25 Feb 2025 2024 FY
Q3 2023 €228,034,000 €53,041,000 -€8,443,000 -14% 01 Jul 2023 30 Sep 2023 6-K 05 Nov 2024 2024 Q3
Q2 2023 €236,477,000 €57,184,000 +€1,766,000 +3.2% 01 Apr 2023 30 Jun 2023 6-K 30 Jul 2024 2024 Q2
Q1 2023 €234,711,000 €55,760,000 +€6,087,000 +12% 01 Jan 2023 31 Mar 2023 6-K 07 May 2024 2024 Q1
Q4 2022 €228,624,000 €62,049,000 -€5,709,000 -8.4% 01 Oct 2022 31 Dec 2022 20-F 25 Feb 2025 2024 FY
Q3 2022 €234,333,000 €61,484,000 +€9,122,000 +17% 01 Jul 2022 30 Sep 2022 6-K 02 Nov 2023 2023 Q3
Q2 2022 €225,211,000 €55,418,000 +€3,401,000 +6.5% 01 Apr 2022 30 Jun 2022 6-K 02 Aug 2023 2023 Q2
Q1 2022 €221,810,000 €49,673,000 +€1,028,000 +2.1% 01 Jan 2022 31 Mar 2022 6-K 09 May 2023 2023 Q1
Q4 2021 €220,782,000 €67,758,000 +€15,330,000 +29% 01 Oct 2021 31 Dec 2021 20-F 20 Feb 2024 2023 FY
Q3 2021 €205,452,000 €52,362,000 +€7,439,000 +17% 01 Jul 2021 30 Sep 2021 6-K 31 Oct 2022 2022 Q3
Q2 2021 €198,013,000 €52,017,000 +€1,511,000 +3% 01 Apr 2021 30 Jun 2021 6-K 02 Aug 2022 2022 Q2
Q1 2021 €196,502,000 €48,645,000 +€2,728,000 +5.9% 01 Jan 2021 31 Mar 2021 6-K 04 May 2022 2022 Q1
Q4 2020 €193,774,000 €52,428,000 +€3,578,000 +7.3% 01 Oct 2020 31 Dec 2020 20-F 22 Feb 2023 2022 FY
Q3 2020 €190,196,000 €44,923,000 +€2,726,000 +6.5% 01 Jul 2020 30 Sep 2020 6-K 02 Nov 2021 2021 Q3
Q2 2020 €187,470,000 €50,506,000 +€2,123,000 +4.4% 01 Apr 2020 30 Jun 2020 6-K 30 Jul 2021 2021 Q2
Q1 2020 €185,347,000 €45,917,000 +€17,319,000 +61% 01 Jan 2020 31 Mar 2020 6-K 06 May 2021 2021 Q1
Q4 2019 €168,028,000 €48,850,000 +€30,063,000 +160% 01 Oct 2019 31 Dec 2019 20-F 22 Feb 2022 2021 FY
Q3 2019 €137,965,000 €42,197,000 +€16,455,000 +64% 01 Jul 2019 30 Sep 2019 6-K 29 Oct 2020 2020 Q3
Q2 2019 €121,510,000 €48,383,000 +€10,735,000 +29% 01 Apr 2019 30 Jun 2019 6-K 30 Jul 2020 2020 Q2
Q1 2019 €110,775,000 €28,598,000 -€3,299,000 -10% 01 Jan 2019 31 Mar 2019 6-K 06 May 2020 2020 Q1
Q4 2018 €114,074,000 €18,787,000 +€2,717,000 +17% 01 Oct 2018 31 Dec 2018 20-F 23 Feb 2021 2020 FY
Q3 2018 €111,357,000 €25,742,000 -€1,953,000 -7.1% 01 Jul 2018 30 Sep 2018 6-K 31 Oct 2019 2019 Q3
Q2 2018 €113,310,000 €37,648,000 +€2,552,000 +7.3% 01 Apr 2018 30 Jun 2018 6-K 30 Jul 2019 2019 Q2
Q1 2018 €110,758,000 €31,897,000 -€239,000 -0.74% 01 Jan 2018 31 Mar 2018 6-K 02 May 2019 2019 Q1
Q4 2017 €110,997,000 €16,070,000 01 Oct 2017 31 Dec 2017 20-F 20 Feb 2020 2019 FY
Q3 2017 €27,695,000 01 Jul 2017 30 Sep 2017 6-K 30 Oct 2018 2018 Q3
Q2 2017 €35,096,000 01 Apr 2017 30 Jun 2017 6-K 01 Aug 2018 2018 Q2
Q1 2017 €32,136,000 01 Jan 2017 31 Mar 2017 6-K 03 May 2018 2018 Q1

Fresenius Medical Care AG Annual Research And Development Expense (EUR)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 €183,493,000 -€48,477,000 -21% 01 Jan 2024 31 Dec 2024 20-F 25 Feb 2025 2024 FY
2023 €231,970,000 +€3,346,000 +1.5% 01 Jan 2023 31 Dec 2023 20-F 25 Feb 2025 2024 FY
2022 €228,624,000 +€7,842,000 +3.6% 01 Jan 2022 31 Dec 2022 20-F 25 Feb 2025 2024 FY
2021 €220,782,000 +€27,008,000 +14% 01 Jan 2021 31 Dec 2021 20-F 20 Feb 2024 2023 FY
2020 €193,774,000 +€25,746,000 +15% 01 Jan 2020 31 Dec 2020 20-F 22 Feb 2023 2022 FY
2019 €168,028,000 +€53,954,000 +47% 01 Jan 2019 31 Dec 2019 20-F 22 Feb 2022 2021 FY
2018 €114,074,000 +€3,077,000 +2.8% 01 Jan 2018 31 Dec 2018 20-F 23 Feb 2021 2020 FY
2017 €110,997,000 -€35,514,000 -24% 01 Jan 2017 31 Dec 2017 20-F 20 Feb 2020 2019 FY
2016 €146,511,000 +€18,383,000 +14% 01 Jan 2016 31 Dec 2016 20-F 20 Feb 2019 2018 FY
2015 €128,128,000 01 Jan 2015 31 Dec 2015 20-F 27 Feb 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.